Verschraegen C F, Legha S S, Hersh E M, Plager C, Papadopoulos N, Burgess M A
University of Texas Health Sciences Center, Department of Internal Medicine, Houston 77030.
Eur J Cancer. 1993;29A(5):708-11. doi: 10.1016/s0959-8049(05)80351-x.
A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous methanol extraction residue (MER) of bacillus Calmette-Guerin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9-24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.
对103例转移性黑色素瘤患者每3周给予一次达卡巴嗪（DTIC）单剂量，随后进行5天长春地辛（VDS）静脉输注。其中一半患者在每个疗程的第7天和第14天除接受化疗外，还随机接受卡介苗（BCG）的静脉甲醇提取物（MER）。98例患者可进行评估。治疗组的缓解率分别为16%和17%（置信区间9 - 24%）。化疗中加入MER后，缓解率和生存率均未提高。除显著的粒细胞减少外，毒性为中度。DTIC与VDS联合使用并不比单独使用DTIC更有效，且增加了神经毒性。
